The Role of Flaxseed in Improving Human Health
Abstract
:1. Introduction
2. Forms of Flaxseed Consumption
3. Hypocholesterolemic Properties of Flaxseed
4. Hypotensive Properties of Flaxseed
5. Hypoglycemic Properties of Flaxseed
6. Anticancer Properties of Flaxseed
7. Anti-Inflammatory Properties of Flaxseed
8. The Effect of Flaxseed on Sex Hormones and Menopause Symptoms
9. Flaxseed and Digestive Health
10. Flaxseed and the Nervous System
11. Flaxseed and the Skin
12. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bernacchia, R.; Preti, R.; Vinci, G. Chemical Composition and Health Benefits of Flaxseed. Austin J. Nutri. Food Sci. 2014, 2, 1045. [Google Scholar]
- Dzuvor, C.K.O.; Taylor, J.T.; Acquah, C.; Pan, S.; Agyei, D. Bioprocessing of Functional Ingredients from Flaxseed. Molecules 2018, 23, 2444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van den Driessche, J.J.; Plat, J.; Mensink, R.P. Effects of superfoods on risk factors of metabolic syndrome: A systematic review of human intervention trials. Food Funct. 2018, 9, 1944–1966. [Google Scholar] [CrossRef] [PubMed]
- Sahoo, A.K.; Ranveer, R.C. Bioactive Components of Flaxseed and its Health Benefits. Int. J. Pharm. Sci. Rev. Res. 2015, 31, 42–51. [Google Scholar]
- Parikh, M.; Netticadan, T.; Pierce, G.N. Flaxseed: Its bioactive components and their cardiovascular benefits. Am. J. Physiol. Heart Circ. Physiol. 2018, 314, H146–H159. [Google Scholar] [CrossRef]
- Guan, Z.-W.; Yu, E.-Z.; Feng, Q. Soluble Dietary Fiber, One of the Most Important Nutrients for the Gut Microbiota. Molecules 2021, 26, 6802. [Google Scholar] [CrossRef]
- Lorenc, F.; Jarošová, M.; Bedrníček, J.; Smetana, P.; Bárta, J. Structural Characterization and Functional Properties of Flaxseed Hydrocolloids and Their Application. Foods 2022, 11, 2304. [Google Scholar] [CrossRef]
- Bekhit, A.E.A.; Shavandi, A.; Jodjaja, T.; Birch, J.; Teh, S.; Ahmed, I.A.M.; Al-Juhaimi, F.Y.; Saeedi, P.; Bekhit, A.A. Flaxseed: Composition, detoxification, utilization, and opportunities. Biocatal. Agric. Biotechnol. 2018, 13, 129–152. [Google Scholar] [CrossRef]
- Edel, A.L.; Aliani, M.; Pierce, G.N. Stability of bioactives in flaxseed and flaxseed-fortified foods. Food Res. Int. 2015, 77, 140–155. [Google Scholar] [CrossRef]
- Parikh, M.; Pierce, G.N. Dietary flaxseed: What we know and don’t know about its effects on cardiovascular disease. Can. J. Physiol. Pharmacol. 2019, 97, 75–81. [Google Scholar] [CrossRef]
- Austria, J.A.; Richard, M.N.; Chahine, M.N.; Edel, A.L.; Malcolmson, L.J.; Dupasquier, C.M.; Pierce, G.N. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J. Am. Coll. Nutr. 2008, 27, 214–221. [Google Scholar] [CrossRef] [PubMed]
- Hadi, A.; Askarpour, M.; Salamat, S.; Ghaedi, E.; Symonds, M.E.; Miraghajani, M. Effect of flaxseed supplementation on lipid profile: An updated systematic review and dose-response meta-analysis of sixty-two randomized controlled trials. Pharmacol. Res. 2020, 152, 104622. [Google Scholar] [CrossRef] [PubMed]
- Soltanian, N.; Janghorbani, M. Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes. Clin. Nutr. ESPEN 2019, 29, 41–48. [Google Scholar] [CrossRef] [PubMed]
- Sadat Masjedi, M.; Mohammadi Pour, P.; Shokoohinia, Y.; Asgary, S. Effects of Flaxseed on Blood Lipids in Healthy and Dyslipidemic Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr. Probl. Cardiol. 2021, 47, 100931. [Google Scholar] [CrossRef] [PubMed]
- Morshedzadeh, N.; Rahimlou, M.; Shahrokh, S.; Karimi, S.; Mirmiran, P.; Zali, M.R. The effects of flaxseed supplementation on metabolic syndrome parameters, insulin resistance and inflammation in ulcerative colitis patients: An open-labeled randomized controlled trial. Phytother. Res. 2021, 35, 3781–3791. [Google Scholar] [CrossRef]
- Yang, C.; Xia, H.; Wan, M.; Lu, Y.; Xu, D.; Yang, X.; Yang, L.; Sun, G. Comparisons of the efects of diferent faxseed products consumption on lipid profiles, infammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases: Systematic review and a dose– response meta-analysis of randomized controlled trials. Nutr. Metab. 2021, 18, 91. [Google Scholar] [CrossRef]
- Khalesi, S.; Irwin, C.; Schubert, M. Flaxseed Consumption May Reduce Blood Pressure: A Systematic Review and Metanalysis of Controlled Trials. J. Nutr. 2015, 145, 758–765. [Google Scholar] [CrossRef] [Green Version]
- Javidi, A.; Mozaffari-Khosravi, H.; Nadjarzadeh, A.; Dehghani, A.; Eftekhari, M.H. The effect of flaxseed powder on insulin resistance indices and blood pressure in prediabetic participants: A randomized controlled clinical trial. J. Res. Med. Sci. 2016, 21, 70. [Google Scholar] [CrossRef]
- Rodriguez-Leyva, D.; Weighell, W.; Edel, A.L.; LaVallee, R.; Dibrov, E.; Pinneker, R.; Maddaford, T.G.; Ramjiawan, B.; Aliani, M.; Guzman, R.; et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension 2013, 62, 1081–1089. [Google Scholar] [CrossRef] [Green Version]
- Toulabi, T.; Yarahmadi, M.; Goudarzi, F.; Ebrahimzadeh, F.; Momenizadeh, A.; Yarahmadi, S. Effects of flaxseed on blood pressure, body mass index, and total cholesterol in hypertensive patients: A randomized clinical trial. Explore 2022, 18, 438–445. [Google Scholar] [CrossRef]
- Hajiahmadi, S.; Nadjarzadeh, A.; Gharipour, M.; Hosseinzadeh, M.; Fallahzadeh, H.; Mohsenpour, M.A. Effect of flaxseed oil on glycemic control and inflammatory markers in overweight adults with pre-diabetes: A double-blind randomized controlled clinical trial. J. Herb. Med. 2020, 24, 100387. [Google Scholar] [CrossRef]
- Almehmadi, A.; Lightowler, H.; Chohan, M.; Clegg, M.E. The effect of a split portion of flaxseed on 24-h blood glucose response. Eur. J. Nutr. 2021, 60, 1363–1373. [Google Scholar] [CrossRef]
- Hutchins, A.M.; Brown, B.D.; Cunnane, S.C.; Domitrovich, S.G.; Adams, E.R.; Bobowiec, C.E. Daily flaxseed consumption improves glycemic control in obese men and women with pre-diabetes: A randomized study. Nutr. Res. 2013, 33, 367–375. [Google Scholar] [CrossRef] [PubMed]
- Dobrowolska, K.; Regulska-Ilow, B. The legitimacy of using dietary supplement diglycoside secoisolariciresinol (SDG) from flaxseed in cancer. Rocz. Panstw. Zakl. Hig. 2021, 72, 9–20. [Google Scholar] [CrossRef] [PubMed]
- Di, Y.; De Silva, F.; Krol, E.S.; Alcorn, J. Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3. Nutr. Cancer 2018, 70, 306–315. [Google Scholar] [CrossRef] [PubMed]
- Tannous, S.; Haykal, T.; Dhaini, J.; Hodroj, M.H.; Rizk, S. The anti-cancer effect of flaxseed lignan derivatives on different acute myeloid leukemia cancer cells. Biomed. Pharmacother. 2020, 132, 110884. [Google Scholar] [CrossRef] [PubMed]
- Buckner, A.L.; Buckner, C.A.; Montaut, S.; Lafrenie, R.M. Treatment with flaxseed oil induces apoptosis in cultured malignant cells. Heliyon 2019, 5, e02251. [Google Scholar] [CrossRef] [Green Version]
- Zou, X.G.; Hu, J.N.; Wang, M.; Du, Y.X.; Li, J.; Mai, Q.Y.; Deng, Z.Y. [1-9-NaC]-linusorb B2 and [1-9-NaC]-linusorb B3 isolated from flaxseed induce G1 cell cycle arrest on SGC-7901 cells by modulating the AKT/JNK signaling pathway. J. Funct. Foods 2019, 52, 332–339. [Google Scholar] [CrossRef]
- Okinyo-Owiti, D.P.; Dong, Q.; Ling, B.; Jadhav, P.D.; Bauer, R.; Maley, J.M.; Reaney, M.J.T.; Yang, J.; Sammynaiken, R. Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment. Toxicol. Rep. 2015, 2, 1014–1018. [Google Scholar] [CrossRef] [Green Version]
- Barthet, V.J.; Klensporf-Pawlik, D.; Przybylski, R. Antioxidant activity of flaxseed meal components. Can. J. Plant Sci. 2014, 94, 593–602. [Google Scholar] [CrossRef] [Green Version]
- Musazadeh, V.; Jafarzadeh, J.; Keramati, M.; Zarezadeh, M.; Ahmadi, M.; Farrokhian, Z.; Ostadrahimi, A. Flaxseed Oil Supplementation Augments Antioxidant Capacity and Alleviates Oxidative Stress: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid. Based Complement. Alternat. Med. 2021, 2021, 4438613. [Google Scholar] [CrossRef] [PubMed]
- Mirfatahi, M.; Tabibi, H.; Nasrollahi, A.; Hedayati, M.; Taghizadeh, M. Effect of flaxseed oil on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients: A randomized controlled trial. Int. Urol. Nephrol. 2016, 48, 1335–1341. [Google Scholar] [CrossRef] [PubMed]
- Ratan, Z.A.; Jeong, D.; Sung, N.Y.; Shim, Y.Y.; Reaney, M.J.T.; Yi, Y.-S.; Cho, J.Y. LOMIX, a Mixture of Flaxseed Linusorbs, Exerts Anti-Inflammatory Effects through Src and Syk in the NF-κB Pathway. Biomolecules 2020, 10, 859. [Google Scholar] [CrossRef] [PubMed]
- Chang, V.C.; Cotterchio, M.; Boucher, B.A.; Jenkins, D.J.A.; Mirea, L.; McCann, S.E.; Thompson, L.U. Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among Postmenopausal Women: A Randomized Controlled Intervention Trial. Nutr. Cancer 2019, 71, 385–398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cetisli, N.E.; Saruhan, A.; Kivcak, B. The effects of flaxseed on menopausal symptoms and quality of life. Holist. Nurs. Pract. 2015, 29, 151–157. [Google Scholar] [CrossRef] [PubMed]
- Ghazanfarpour, M.; Sadeghi, R.; Latifnejad Roudsari, R.; Khadivzadeh, T.; Khorsand, I.; Afiat, M.; Esmaeilizadeh, M. Effects of flaxseed and Hypericum perforatum on hot flash, vaginal atrophy and estrogen-dependent cancers in menopausal women: A systematic review and meta-analysis. Avicenna J. Phytomed. 2016, 6, 273–283. [Google Scholar]
- Colli, M.C.; Bracht, A.; Soares, A.A.; de Oliveira, A.L.; Bôer, C.G.; de Souza, C.G.; Peralta, R.M. Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms. J. Med. Food 2012, 15, 840–845. [Google Scholar] [CrossRef]
- Lagkouvardos, I.; Kläring, K.; Heinzmann, S.S.; Platz, S.; Scholz, B.; Engel, K.H.; Schmitt-Kopplin, P.; Haller, D.; Rohn, S.; Skurk, T.; et al. Gut metabolites and bacterial community networks during a pilot intervention study with flaxseeds in healthy adult men. Mol. Nutr. Food Res. 2015, 59, 1614–1628. [Google Scholar] [CrossRef]
- Soltanian, N.; Janghorbani, M. A randomized trial of the effects of flaxseed to manage constipation, weight, glycemia, and lipids in constipated patients with type 2 diabetes. Nutr. Metab. 2018, 15, 36. [Google Scholar] [CrossRef] [Green Version]
- Brahe, L.; Le Chatelier, E.; Prifti, E.; Pons, N.; Kennedy, S.; Blædel, T.; Håkansson, J.; Dalsgaard, T.K.; Hansen, T.; Pedersen, O.; et al. Dietary modulation of the gut microbiota—A randomised controlled trial in obese postmenopausal women. Br. J. Nutr. 2015, 114, 406–417. [Google Scholar] [CrossRef] [Green Version]
- Ramos, C.I.; Andrade de Lima, A.F.; Grilli, D.G.; Cuppari, L. The short-term effects of olive oil and flaxseed oil for the treatment of constipation in hemodialysis patients. J. Ren. Nutr. 2015, 25, 50–56. [Google Scholar] [CrossRef] [PubMed]
- Kristensen, M.; Jensen, M.G.; Aarestrup, J.; Petersen, K.E.; Søndergaard, L.; Mikkelsen, M.S.; Astrup, A. Flaxseed dietary fibers lower cholesterol and increase fecal fat exrection, but magnitude of effect depend on food type. Nutr. Metab. 2012, 9, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sant’Ana, C.T.; Amorim, A.D.; Gava, A.P.; Aguilar, C.M.; Silva, N.G.; Machado, L.D.; Viana, M.L.; Oliveira, D.D.S.; Silva, P.I.; Costa, N.M.B.; et al. Brown and golden flaxseed reduce intestinal permeability and endotoxemia, and improve the lipid profile in perimenopausal overweight women. Int. J. Food Sci. Nutr. 2022, 73, 829–840. [Google Scholar] [CrossRef]
- Gholami, Z.; Akhlaghi, M. The effect of flaxseed on physical and mental fatigue in children and adolescents with overweight/obesity: A randomised controlled trial. Br. J. Nutr. 2021, 126, 151–159. [Google Scholar] [CrossRef]
- Poorbaferani, F.; Rouhani, M.H.; Heidari, Z.; Poorbaferani, M.; Safavi, S.M. Flaxseed oil supplementation on severity of depression and brain-derived neurotrophic factor: A randomized, double blind placebo controlled clinical trial. Int. J. Food Prop. 2020, 23, 1518–1526. [Google Scholar] [CrossRef]
- Neukam, K.; De Spirt, S.; Stahl, W.; Bejot, M.; Maurette, J.M.; Tronnier, H.; Heinrich, U. Supplementation of flaxseed oil diminishes skin sensitivity and improves skin barrier function and condition. Skin Pharmacol. Physiol. 2011, 24, 67–74. [Google Scholar] [CrossRef]
- Soleimani, Z.; Hashemdokht, F.; Bahmani, F.; Taghizadeh, M.; Memarzadeh, M.R.; Asemi, Z. Clinical and metabolic response to flaxseed oil omega-3 fatty acids supplementation in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. J. Diabetes Complicat. 2017, 31, 1394–1400. [Google Scholar] [CrossRef]
Biological Activities and the Related Diseases | Compounds Responsible for Biological Activity | Form of Flaxseed | Design of Clinical Trials | Results of the Clinical Trials |
---|---|---|---|---|
Improvement in lipid profile; decreased risk of heart diseases | α-linolenic acid, phenolic compounds, lignans, dietary fiber | Flaxseed pre-mixed in cookies | 77 participants; 12-week intervention Intervention group: 10 g of flaxseed or psyllium pre-mixed in cookies per day; control group: cookies without any additives | Reduced total cholesterol level (36.9 mg/dL; p < 0.001), LDL-C (21 mg/dL; p < 0.001), and TG (12.3 mg/dL; p = 0.045); improved HDL-C (6.0 mg/dL; p = 0.316) in the flaxseed group [13] |
Flaxseed oil, roasted flaxseed, ground flaxseed, raw flaxseed | In the group of healthy participants: 2 to 30 g/d of flaxseed; in the group of participants with lipid metabolic disorders: 15 to 40 g per day of flaxseed | Improvement in lipid profile in healthy participants with BMI >25 kg/m2 (SMD: −28.7); (95% CI −54.67–−2.62); (p = 0.031), and in dyslipidemic participants (SMD: −1.41); (95% CI −2.30–−0.79); (p < 0.001); improvement in LDL-C (SMD: −0.69); (95% CI −1.13–−0.25); (p = 0.002), and reduced TG in dyslipidemic participants (SMD: −1.47); (95% CI −2. 21–−0.72); (p < 0.001); increased HDL-C in healthy (SMD: 5.12); (95% CI 2.34–7.90); (p = 0.006) and overweight participants (SMD: 7.92); (95% CI 2.95–12.88); (p = 0.002) with flaxseed supplementation [14] | ||
Ground flaxseed | 70 participants; 12-week intervention Intervention group: 30 g of ground flaxseed per day; control group: normal diet without flaxseed supplementation | Reduction in TG (−13.07 ± 8.31 mg/dL; p < 0.001), and total cholesterol (−16.50 ± 10.87 mg/dL; p < 0.001) and increase in HDL-C (3.67 ± 2.82 mg/dL; p = 0.04) in the flaxseed group [15] | ||
Hypotensive properties; decreased risk of hypertension and other cardiovascular conditions | α-linolenic acid, lignans, dietary fiber | Flaxseed powder | 99 participants; 12-week intervention with a control group; intervention groups: 20 or 40 g of flaxseed powder per day | The 40 g group had a significantly lowered SBP (12.24 ± 23.08 mmHg) compared to the 20 g group (2.56 ± 5.99 mmHg) and the control (−1.5 ± 6.3 mmHg) [18] |
Ground flaxseed | 110 participants; 6-month intervention with a control group; intervention group: 30 g of ground flaxseed per day | Significant reduction in SBP (−10 mmHg; p = 0.04) and DBP (−7 mmHg; p = 0.004) in the flaxseed group; patients who had elevated BP at the baseline: reduction of 15 mmHg in SBP (p = 0.002) and 7 mmHg in DBP (p = 0.003) [19] | ||
Flaxseed powder | 112 participants with hypertension; 12-week intervention with a control group; intervention groups: 10 or 30 g of flaxseed per day | Decrease in SBP (−13.38 mmHg; p = 0.001) and DBP (−5.6 mmHg; p = 0.001) in the 30 g group [20] | ||
Hypoglycemic properties; decreased risk of type 2 diabetes and insulin resistance | Dietary fiber, α-linolenic acid | Flaxseed pre-mixed in cookies | 77 participants; 12-week intervention; intervention groups: 10 g of flaxseed or psyllium pre-mixed in cookies per day; control group received placebo cookies without any additives | Significantly improved fasting glucose (−27.8 mg/dL; p = 0.004) in the flaxseed group [13] |
Flaxseed powder | 99 participants; 12-week intervention with a control group; intervention groups: 20 or 40 g of flaxseed powder per day | Reduced HOMA-IR in the group consuming 20 g of flaxseed (0.27 ± 0.65; p = 0.033); significant reduction in fasting glucose in all study participants [18] | ||
Flaxseed powder | 25 participants overweight or obese with pre-diabetes; 12-week study; participants consumed 0 g, 13 g, or 26 g of flaxseed powder per day | Fasting glucose (−2 mg/dL; p = 0.036), insulin (−1.9 mU/L; p = 0.013), and HOMA-IR (−0.6; p = 0.008) significantly decreased in the 13 g group compared to the 26 g group and placebo [23] | ||
Anticancer properties | Lignans, linoorbitides, α-linolenic acids | - | Breast cancer cell lines (SKBR-3 and MDA-MB-231) were divided into two groups; the first was treated with the combination of chemotherapeutic agents and flaxseed lignans for 72 h, and the second was treated only with chemotherapeutic agents | Flaxseed lignans significantly enhanced the cytotoxicity of chemotherapeutic agents against breast cancer cells; the combination of ENL and metformin together in combination with low concentrations of chemotherapeutic drugs was more effective in decreasing cancer cell viability compared to the individual chemotherapeutic drug alone [25] |
- | Acute myeloid leukemia cell lines and a normal lymphoblastic cell line were cultured and treated with various concentrations of the purified flaxseed lignans | After 24 h, 48 h, and 72 h, the percent proliferation of the cells treated with 100 µM of ENL significantly decreased, reaching 55% (p < 0.0001), 46% (p < 0.0001), and 29% (p < 0.0001) in the KG-1 cell line, respectively; and 55% (p < 0.0001), 46% (p < 0.0001), and 40% (p < 0.0001) in the Monomac-1 cell line, respectively; ENL induces apoptosis and increases cellular and DNA fragmentation [26] | ||
- | Treatment of a variety of cancer cell lines with 0.3% or 0.9% flaxseed oil for 4–6 days | Cancer cells treated with a 10−5 or 10−6 M mixture of fatty acids and the lignans reduced cell growth; treatment with 0.3% flaxseed oil decreased the number of cells by about 50% and treatment with 0.9% flaxseed oil completely inhibited B16-BL6 cell growth [27] | ||
- | SGC-7901 cells were treated with various concentrations of [1–9-NαC]-linusorb B2 or B3 (80, 120, and 200 μM) for 24 h and subjected to flow cytometric analysis to examine the DNA content after PI staining; the expression levels of CDK2, CDK4, cyclin D3, cyclin E, and p27KIP1 were measured using Western blotting assay | Cell population in the G1 phase of the cell cycle increased from 33.53 ± 1.46% to 35.30 ± 1.59%, 40.03 ± 2.33%, and 46.30 ± 1.45% after treatment with [1–9-NαC]-linusorb B3 of 80, 120, and 200 μM, respectively; the percentage in G1 phase reached 43.50 ± 2.05%, 49.96 ± 1.90%, and 56.45 ± 0.72%, following exposure to [1–9-NαC]-linusorb B2 of 80, 120, and 200 μM, respectively; downregulation of CDK2, CDK4, cyclin D3, and cyclin E, as well as upregulation of p21WAF1/CIP1 and p27KIP1; the disruption of both JNK and AKT played a pivotal role in [1–9-NαC]-linusorb B2-induced G1 phase arrest, but only JNK was involved in [1–9-NαC]-linusorb B3-induce G1 phase arrest [28] | ||
- | Human breast cancer cell lines and melanoma cell lines were divided into two groups and cultured for 24 h and 48 h; then, were treated with different concentrations of linoorbitides | Cytotoxicity of linoorbitides against cancer cells was cell-type-specific and concentration-dependent [29] | ||
Anti-inflammatory properties | Lignans, phenolic acids, tocopherols, linusorbs | Flaxseed oil | 34 participants with hemodialysis; 8-week intervention; intervention group: 6 g of flaxseed oil per day Control group: 6 g of medium-chain fatty acids (59.4% caprylic acid, 39.6% capric acid, 0.7% caproic acid, 0.2% lauric acid, and 0.1% myristic acid) | Reduction in hs-CRP (−1.4 ± 0.5 mg/L; p = 0.05) and sVCAM-1 (−23.0 ± 10.0 mg/mL; p = 0.05) levels in the flaxseed oil group [32] |
- | RAW264.7 and HEK293 cells were treated with either LOMIX (0–200 g/mL), L-NAME (0–1 mM), Pred (0–100 µM), or individual linusorb; then, several in vitro assays (i.e., NO production, real-time PCR analysis, Western blot analysis) and in vivo analyses were carried out | Inhibition of NO production, cell shape changes, and inflammatory gene expression in stimulated RAW264.7 cells through direct targeting of Src and Syk in the NF-κB pathway; alleviation of symptoms of gastritis, colitis, and hepatitis in murine model systems mediated via inhibition of Src I Syk [33] | ||
Influence on the concentration of female sex hormones; reduced risk of breast cancer | Lignans | Ground flaxseed | 99 postmenopausal women; 7-week intervention; intervention group: 2 tablespoons (15 g) of ground flaxseed daily Control group: women on a normal diet | Significant increase in total enterolignans (62.3 mg/mL; p < 0.001), serum 2-hydroxyestrone concentration (TER: 1.54 pg/mL; 95% CI: 1.18–2.00; p = 0.002), and 2:16α-hydroxyestrone ratio (TER: 1.54; 95% CI: 1.15–2.06; p = 0.004); change in enterolignan level was positively correlated with changes in 2-hydroxyestrone and 2:16α-hydroxyestrone ratio, and negatively correlated with prolactin levels [34] |
Reduction in menopausal symptoms | Lignans | No data available | 140 menopausal women; 3-month intervention with a control group; intervention groups: the first group received 5 g of flaxseed daily, the second group received hormone replacement therapy and 5 g of flaxseed daily, and the third group used hormone replacement therapy | Significant decrease in menopausal symptoms and increase in quality of life in women consuming flaxseed. The intensity of menopausal symptoms decreased by 8.7% and 9.8% in two intervention groups (p < 0.05) being supplemented with flaxseed [35] |
Flaxseed extract, ground flaxseed | 90 menopausal women; 6-month intervention; intervention groups: 1 g of flaxseed extract containing at least 100 mg of SDG, or 90 g of ground flaxseed containing at least 270 mg of SDG per day Control group: 1 g of collagen daily | In the flaxseed extract group, Kupperman index and hot flashes were reduced by 2.5 (p = 0.007) and 1.6 (p = 0.001), respectively, and in the ground flaxseed group by 3.05 (p = 0.005) and 1.04 (p = 0.035) compared to the control group [37] | ||
Regulation of gut microbiota | Lignans, soluble fiber | Ground flaxseed | 9 healthy men; 1-week intervention; each participant ingested 0.3 g of flaxseed for each kg of body weight per day | Significant increase in ENL blood concentration, accompanied by fecal excretion of propionate and glycerol; ENL production was linked to the abundance of Ruminococcus bromii and Ruminococcus lactaris [38] |
Flaxseed mucilage | 58 obese postmenopausal women; 6-week intervention with a control group; intervention groups: daily intake of L. paracasei F19 or 10 g of flaxseed mucilage | Alterations in abundance of thirty-three metagenomic species (p < 0.01), including decreased relative abundance of eight Faecalibacterium species in the flaxseed mucilage group [40] | ||
Increase in the frequency of evacuation and improved consistency of stools; prevention of constipation | Dietary fiber, flaxseed oil | Baked flaxseed | 53 constipated patients with T2D with BMI 20.5–48.9 kg/m2; 12-week intervention; 10 g of flaxseed pre-mixed in cookies twice per day or placebo cookies for 12 weeks | Significantly improved constipation symptoms, particularly stool consistency [39] |
Flaxseed oil | 50 constipated patients; 4-week intervention; intervention groups: the mineral oil group, the olive oil group, and the flaxseed oil group The initial oil dose was 4 mL/day, and adjustments during the follow-up could be made as needed. The average consumption of flaxseed oil was 6.9 ± 2.7 mL per day | The Rome III score improved significantly in patients receiving mineral oil (10.5 ± 5.0 to 4.1 ± 4.0; p < 0.01), olive oil (10.3 ± 4.2 to 3.2 ± 3.8; p < 0.01), and flaxseed oil (9.6 ± 4.2 to 6.0 ± 5.1; p < 0.01), with no significant group-by-time interaction (p < 0.15). The scores of 5 from 6 constipation symptoms reduced similarly in the mineral oil and olive oil groups, whereas only the frequency of evacuation and the consistency of stools improved in the flaxseed oil group [41] | ||
Increased fecal fat excretion; prevention of being overweight and of obesity | Soluble dietary fiber | Flaxseed fiber drink, flaxseed fiber bread |
17 participants; one-week intervention; intervention groups: a diet with flaxseed fiber drink or with flaxseed fiber bread Control group: low-fiber diet | Participants drinking flaxseed fiber drinks excreted 4.96 ± 0.31 g/d of fat, as compared to only 3.20 ± 0.33 g fat/d with the control diet, corresponding to a 55% increase. Participants eating flaxseed fiber bread eliminated 3.76 ± 0.31 g/d of fat with feces (p < 0.001) [42] |
Reduction in mental fatigue | α-linolenic acid | Uncooked ground flaxseed | 72 children and adolescents with a BMI > 25 kg/m2; 4-week intervention; intervention group: 20 g of flaxseed daily Control group: 25 g of puffed wheat daily | Significant reduction in mental fatigue in the group consuming flaxseed [44] |
Reduction in or elimination of depression symptoms | α-linolenic acid | Flaxseed oil | 60 depressed women; 10-week intervention with a control group; intervention group: 1000 mg of flaxseed oil capsule twice a day | Increase in serum BDNF concentration (1.12 ± 0.6 pg/mL vs. 0.2 ± 0.56 pg/mL; p < 0.001) and decrease in total BDI-II score (−16.62 ± 7.03 vs. −8.45 ± 7.8; p < 0.001) in the intervention group [45] |
Improvement in skin condition | α-linolenic acid | Flaxseed oil | 26 women with sensitive skin; 12-week intervention; intervention group: 4 capsules of flaxseed oil (555,32 mg/capsule) per day Control group: 4 capsules of safflower oil (560 mg/capsule) per day | Significant decrease in sensitivity, skin roughness, scaling, and transepidermal water loss, while epidermal hydration and smoothness were increased in the intervention group [46] |
Improvement in wound healing | Omega-3 fatty acids | Flaxseed oil | 60 participants with grade 3 diabetic foot syndrome; 12-week intervention; intervention group: 1000 mg of omega-3 fatty acids from flaxseed oil twice a day | Significant reduction in the length and depth of ulcers in the intervention group [47] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nowak, W.; Jeziorek, M. The Role of Flaxseed in Improving Human Health. Healthcare 2023, 11, 395. https://doi.org/10.3390/healthcare11030395
Nowak W, Jeziorek M. The Role of Flaxseed in Improving Human Health. Healthcare. 2023; 11(3):395. https://doi.org/10.3390/healthcare11030395
Chicago/Turabian StyleNowak, Wioletta, and Małgorzata Jeziorek. 2023. "The Role of Flaxseed in Improving Human Health" Healthcare 11, no. 3: 395. https://doi.org/10.3390/healthcare11030395
APA StyleNowak, W., & Jeziorek, M. (2023). The Role of Flaxseed in Improving Human Health. Healthcare, 11(3), 395. https://doi.org/10.3390/healthcare11030395